Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 mai 2015 18h00 HE | Source: TESARO, Inc.

TESARO Announces Successful Completion of Rolapitant Bioequivalence Study

WALTHAM, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the successful completion of the rolapitant bioequivalence...
30 mai 2015 14h00 HE | Source: TESARO, Inc.

TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab)

WALTHAM, Mass. and KENILWORTH, N.J., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE:MRK), known as MSD outside the United...
20 mai 2015 08h01 HE | Source: TESARO, Inc.

TESARO Announces Webcast of Presentation at the Jefferies 2015 Global Healthcare Conference

WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced today that Lonnie Moulder, CEO of TESARO, will present an overview...
14 mai 2015 09h37 HE | Source: TESARO, Inc.

TESARO Announces Election of Garry A. Nicholson to Board of Directors and Results of Annual Stockholder Meeting

WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the results of its Annual Stockholder Meeting, which was...
13 mai 2015 17h30 HE | Source: TESARO, Inc.

TESARO Announces Seven Abstracts to Be Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of seven abstracts at the 2015 American...
30 avr. 2015 16h02 HE | Source: TESARO, Inc.

TESARO Announces Completion of Targeted Enrollment in Phase 3 NOVA Trial and Initiation of the QUADRA Trial of Niraparib

Both the non-germline and germline BRCA mutation cohorts within NOVA are fully enrolled Phase 3 data from NOVA is expected in Q4 2015 Patients are now being treated within the QUADRA...
30 avr. 2015 16h01 HE | Source: TESARO, Inc.

TESARO Announces First-Quarter 2015 Operating Results

Target enrollment completed for both cohorts of the niraparib Phase 3 NOVA trial; data expected in Q4 2015 QUADRA trial of niraparib initiated; initial data anticipated in early 2016 U.S....
23 avr. 2015 08h01 HE | Source: TESARO, Inc.

TESARO Launches Campaign to Raise Awareness of Chemotherapy-Induced Nausea and Vomiting Among Patients With Cancer

WALTHAM, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the launch of Ask About CINV, a campaign to raise...
22 avr. 2015 08h01 HE | Source: TESARO, Inc.

TESARO Announces Participation at Three Investor Conferences

WALTHAM, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three investor conferences during the...
16 avr. 2015 08h01 HE | Source: TESARO, Inc.

TESARO to Announce First-Quarter Financial Results on April 30, 2015

WALTHAM, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first-quarter 2015 financial results on Thursday, April 30, 2015, after the close of the U.S. financial...

Page précédente